

### PATENT APPLICATION

### UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q88123

Kenji MATSUDA, et al.

Appln. No.: 10/537,462

Group Art Unit: 1617

Confirmation No.: 4737

Examiner: Layla Soroush

02 FC:1806

Filed: June 3, 2005

PROPOFOL-CONTAINING FAT EMULSIONS For:

# SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.97 and 1.98

MAIL STOP AMENDMENT

09/18/2006 MBERHE 60000087 194880 10537462 180.00 DA

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith. All of the listed documents were previously listed in the Form PTO/SB/08 A & B (modified) filed on June 3, 2005.

The present Information Disclosure Statement is being filed (without a Statement Under 37 C.F.R § 1.97(e)) after the later of three months from the application's filing date and the mailing date of the first Office Action on the merits, but before a Final Office Action, Notice of Allowance, or an action that otherwise closes prosecution in the application (whichever is

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

U.S. Application No.: 10/537,462

earlier), and therefore the PTO is authorized to charge Deposit Account 19-4880, the fee of

\$180.00 under 37 C.F.R. § 1.17(p).

In compliance with the concise explanation requirement under 37 C.F.R. § 1.98(a)(3) for

Docket No.: Q88123

foreign language documents, Applicant encloses herewith a copy of an International Search

Report (ISR) citing such documents, indicating the degree of relevance found by the

International Bureau. In addition, Applicant submits herewith an English language abstract of JP

2002-179562.

The submission of the listed documents is not intended as an admission that any such

document constitutes prior art against the claims of the present application. Applicant does not

waive any right to take any action that would be appropriate to antedate or otherwise remove any

listed document as a competent reference against the claims of the present application.

The statutory fee of \$180.00 is being charged to Deposit Account No. 19-4880 via EFS

Payment Screen. The USPTO is also directed and authorized to charge all required fees, except

for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit

any overpayments to said Deposit Account.

Respectfully submitted,

Registration No. 51,283

Fang Liu

SUGHRUE MION, PLLC

Telephone: (202) 293-7060

Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: September 14, 2006

2

# Substitute for Form 1449 A & B/PTO SUPPLEMENTAL INFORMATION DISCL

Sheet

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

Complete if Known				
Application Number	10/537,462			
Confirmation Number	4737			
Filing Date	June 3, 2005			
First Named Inventor	Kenji MATSUDA			
Art Unit	1617			
Examiner Name	Layla Soroush			
Attorney Docket No.	Q88123			

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Document Number		Publication Date		
		Number	Kind Code <sup>2</sup> (if known)	MM-DD-YYYY	Name of Patentee or Applicant of Cited Documer	
		US				
		US				
		US				
		US				
		US	-			
		US				
		US				
		US				
		US				

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date	Name of Patentee or	77
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)	MM-DD-YYYY	1 · · · ·	Translation <sup>6</sup>
		wo	01/97779	A2	12-27-2001	RTP PHARMA INC.	
		WO	00/10531	Al	03-02-2000	RTP PHARMA INC.	
		wo	01/01960	A1	01-11-2001	LIPOCINE, INC.	
		wo	00/74653	Al	12-14-2000	SKYEPHARMA, INC.	
		wo	97/34588	Al	09-25-1997	RESEARCH TRIANGLE PHARMACEUTICALS LTD.	
		JP	2002-179562	A	06-26-2002	Towa Yakuhin Kabushi kaisha	Abstract
		<del> </del>					
		ļ					

NON PATENT LITERATURE DOCUMENTS					
Examiner Cite Initials* No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.			
		International Search Report mailed March 02, 2004			
			ļ <u> </u>		
			ļ		
			<del>                                     </del>		
			J		

	 <del></del>		
Examiner Signature	 	Date Considered	 

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or follow the hyperlink from the title of the document to the intranet. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>3</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to indicate here if English language Translation is attached.